Suggestions
Derrell Porter
Founder & CEO at Cellevolve Bio
Dr. Derrell D. Porter is a physician-entrepreneur and biopharmaceutical executive with over 20 years of experience in drug development, commercialization, and corporate strategy. He is currently the Chief Executive Officer of CTRL Therapeutics, a company focused on next-generation cell therapies for solid tumors, and serves as a Board Member at Portal Innovations, LLC, a venture development firm supporting early-stage biotech companies. Additionally, he holds board positions at Acumen Pharmaceuticals and Passage Bio.123
Dr. Porter previously founded Cellevolve Bio, a biotech company focused on cell therapy for neglected diseases. His career includes leadership roles at prominent companies such as Gilead Sciences, AbbVie, Amgen, and Atara Biotherapeutics. He has expertise in global commercialization and strategic development across various therapeutic areas.13
He earned his M.D. from the Perelman School of Medicine at the University of Pennsylvania, an MBA from The Wharton School, and a bachelor’s degree in psychobiology and neuroscience from UCLA.12
Highlights
Earlier this year, we announced a global collaboration with Seattle Children's Therapeutics and The Cure Factory on the BrainChild research program. This has the potential to transform the lives of children with CNS tumors, the #1 cause of childhood cancer deaths. Historically, there have been at least two challenges in developing effective therapies for CNS tumors. First, they express multiple targets or antigens. In other words, the tumor is heterogeneous and can express different targets at different times. Another challenge has been getting the therapy to the tumor. In cancers located in the brain, the therapy must cross the blood brain barrier to reach the tumor if administered in other parts of the body. These two challenges, among others, have complicated developing therapies for years. Remarkably, the team at Seattle Children’s Therapeutics, led by michael jensen, md designed and engineered a multiplex CAR-T program called BrainChild, that is designed to overcome these hurdles. Ultimately, the goal is to develop a therapeutic that will recognize four commonly expressed antigens on CNS tumors that is administered directly to the CNS, in small doses over time. This program consists of five separate CAR T’s. Three are single targeted – BrainChild 01, 02, 03; and two are CAR T’s with multiplexed specificities covering four targets commonly expressed on pediatric brain tumors as a strategy to overcome tumor heterogeneity– BrainChild 04 and 05. The first three are in Phase 1 clinical development and are laying the foundation for the next programs to advance in clinical development. We at Cellevolve are excited about the immense potential of BrainChild and our collaboration with Seattle Children’s and The Cure Factory. We are excited to share a 30 min video below from VOA which highlights the promise and potential of this endeavor, most notably BrainChild 03, which is targeting B7H3 and increasingly used for a specific type of pediatric brain cancer called diffuse intrinsic pontine glioma (DIPG). We are honored to partner with the Seattle Children’s to advance this program and the promise of delivering a new therapy to children who desperately need it. More to come.
#CART #celltherapy #pediatricCNS
